Telix Announces Abstract Presentations at BNMS Annual Spring Meeting

Melbourne (Australia) | 14 May 2024 Telix today announces three abstract presentations featuring the Company’s theranostic programs at the British Nuclear Medicine Society (BNMS) Annual Spring Meeting being held in Belfast, Northern Ireland this week.   Today, Telix’s successful Phase III ZIRCON Study1 of TLX250-CDx (Zircaix®2 89Zr-DFO-girentuximab) in clear cell renal cell carcinoma will be featured in two presentations including a cutting-edge research Power Pitch highlights session.   In addition, TLX66 (90Y-besilesomab), Telix’s investigational bone marrow conditioning therapy will be featured in an oral presentation by Gemma Lewis during the physics dosimetry session.   BNMS presentation details are as follows:   Title: Feasibility of single-timepoint imaging for organ dosimetry in [90Y]Anti-CD66 therapy  Presenter: Gemma Lewis, Southampton General Hospital  Date and Time: Tuesday, 14 May | 9:45 am – 10:00 am  Session: Physics dosimetry abstracts  Location: Room 1  Title: Assessing Radiation Risks with 89Zr-girentuximab   Presenter: Adnan Chowdhury, Royal Free Hospital  Date and Time: Tuesday, 14 May | 10:30 am – 11:00 am  Location: Exhibition Hall  Title: 89Zr-DFO-girentuximab PET-CT imaging can accurately detect clear cell renal cell carcinoma primary and secondary lesions in patients with renal masses at conventional imaging, results from ZIRCON phase III study  Presenter: Dr Thomas Wagner, Royal Free Hospital    Date and Time: Tuesday, 14 May | 12:19 pm to 12:26 pm  Session: Cutting edge research (including research power pitches)  Location: Hall 2  To register, please visit the website here.   TLX250-CDx and TLX66 have not received a marketing authorisation in any jurisdiction. ClinicalTrials.gov ID: NCT03849118  ↩︎ Zircaix® brand name is subject to final regulatory approval.  ↩︎

The release as fetched from its publisher. telixpharma.com ↗